Global biotechnology company Amicus Therapeutics makes the most of its one of a kind platform technologies and medicines to deliver benefits to the rare and orphan disease community.
In late stage development, Amicus Therapeutics lead product candidate, migalastat, will treat people with Fabry disease based on their genetic diagnosis (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/). Another lead product candidate, SD-101, designed to gain consumer confidence, is a therapy for the uncommon hereditary connective tissue disorder Epidermolysis Bullosa.
In addition, Amicus Therapeutics is also driving novel enzyme replacement therapy brands for Pompe disease, Fabry disease, and other illnesses.
John Crowley, chairman and chief executive officer at Amicus Therapeutics emphasized what differentiates Amicus Therapeutics from other companies is how it keeps up an empathetic and caring focus on not only its patients but also their caregivers and families.
He explained how that point of view is built into everything from team meetings to the board of directors. He added the company also tries to base its decisions as if they were undergoing treatment themselves.
Expanding on its patient-centric perspective, Amicus Therapeutics acquired
privately-held biopharmaceutical company, Scioderm in 2015. Crowley said in a statement the acquisition is an excellent strategic match to build advanced therapies for both devastating unusual and orphan diseases.
In 2013, Amicus Therapeutics acquired privately-held competitor Callidus Biopharma, which focuses on enzyme replacement therapies (ERTs)for Pompe disease, according to (en.wikipedia.org/wiki/Amicus_Therapeutics).
Amicus Therapeutics said it will take part in a conference call and live audio webcast on August 7 to talk about the financial results for the second quarter ended June 30, 2017.
Crowley will moderate the call and additional members of his team will also participate in the event.
According to PR Newswire, Amicus Therapeutics stock surged 48.78 percent in the last month and 80.08 percent over the previous three months (PhillyPurge).
What’s more, Amicus Therapeutics was the recipient of a $500,000 grant from the Michael J. Fox Foundation in 2010 and that same year it received a $210,300 grant from the Alzheimer’s Drug Discovery Foundation.
Amicus Therapeutics, which was founded in 2002, is based in Cranbury, New Jersey. The company has a second research site in San Diego, California.